Lanean...
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain
Resistance to the BRAF inhibitor vemurafenib poses a significant problem for the treatment of BRAFV600E-positive melanomas. It is therefore critical to prospectively identify all vemurafenib-resistance mechanisms prior to their emergence in the clinic. The vemurafenib-resistance mechanisms described...
Gorde:
| Argitaratua izan da: | Pigment Cell Melanoma Res |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2013
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4260813/ https://ncbi.nlm.nih.gov/pubmed/24112705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12171 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|